Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
about
Creatine for Parkinson's diseaseCoenzyme Q10 for Parkinson's diseaseCoenzyme Q10 for Parkinson's diseaseDisability Rating Scales in Parkinson's Disease: Critique and Recommendations.Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.Neuroinflammation and neuroimmune dysregulation after acute hypoxic-ischemic injury of developing brainMinocycline development for acute ischemic strokeEffects of age, stage of disease, and educational level on cognitive dysfunction in non-demented idiopathic Parkinsonism: A preliminary reportPredictors of time to initiation of symptomatic therapy in early Parkinson's disease.CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Rankin scale as a potential measure of global disability in early Parkinson's disease.Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions.Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.
P2860
Q24193947-41F9F96A-0DF1-4E9B-846C-ED3DE5249DC7Q24198033-C9DACE52-5C55-48DB-990B-82C698BEBE93Q24234491-034601BA-5795-4DAC-8908-DE5DE0E310B0Q30250276-73D9790F-3E71-4C5B-8D12-3154B67EDE09Q30357397-9471CE8F-EBFC-4958-AE80-BF1FD3F77288Q33753874-88881127-7593-4B27-BD0A-B5E7574F734BQ34091447-7CDC6A53-A38D-413E-B10D-C3B8644C6802Q34301396-0C98F2C5-B485-4F64-BC90-27876EAF7058Q34954213-37425942-3609-433B-8B4D-E7D1B7A3EBECQ35202559-51BB71D1-FE8E-4F18-A9DD-6C8C3A2C6138Q36917623-DDA2C7EB-0328-4936-BBF0-F0CC102BEFEFQ37062111-1C74C63F-D8DF-4123-8E96-B5D665935B5AQ37272860-A03F3D24-0C4A-42FF-8626-70A4C9F6F8B9Q37627352-DCE0A14F-3881-4841-B54E-79440938A441Q39583380-26F9DFDD-096C-405C-BA16-FEAD879EF8C5Q48165108-09407FF1-671B-4007-9138-512197B75F42Q51759987-40269BCC-4010-4E3B-BCFC-4D96DE6EA8BD
P2860
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Determinants of the timing of ...... n Disease (NET-PD) Experience.
@ast
Determinants of the timing of ...... n Disease (NET-PD) Experience.
@en
type
label
Determinants of the timing of ...... n Disease (NET-PD) Experience.
@ast
Determinants of the timing of ...... n Disease (NET-PD) Experience.
@en
altLabel
Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease
@en
prefLabel
Determinants of the timing of ...... n Disease (NET-PD) Experience.
@ast
Determinants of the timing of ...... n Disease (NET-PD) Experience.
@en
P2093
P2860
P1433
P1476
Determinants of the timing of ...... n Disease (NET-PD) Experience.
@en
P2093
Barbara C Tilley
Christopher J Swearingen
G Webster Ross
Grace S Liang
Ivan Bodis-Wollner
Kevin M Biglan
Lisa M Shulman
NET-PD Investigators
Sotirios A Parashos
P2860
P304
P356
10.1001/ARCHNEUROL.2009.159
P577
2009-07-13T00:00:00Z